1. Gefitinib enhances sensitivity of endometrial cancer cells to progestin therapy via dual-specificity phosphatase 1
   Yuan Yang et al, 2017, Oncotarget CrossRef
2. PAC-5 Gene Expression Signature for Predicting Prognosis of Patients with Pancreatic Adenocarcinoma
   Jieun Kim et al, 2019, Cancers CrossRef
3. T2-weighted imaging-based radiomic-clinical machine learning model for predicting the differentiation of colorectal adenocarcinoma
   Hui-Da Zheng et al, 2024, World Journal of Gastrointestinal Oncology CrossRef
4. Mechanisms of resistance to EGFR tyrosine kinase inhibitors
   Lihua Huang et al, 2015, Acta Pharmaceutica Sinica B CrossRef
5. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma
   Cong Liu et al, 2022, Frontiers in Medicine CrossRef
6. Association between the overexpression of Her3 and clinical pathology and prognosis of colorectal cancer
   Qingying Yan et al, 2018, Medicine CrossRef
7. The power of heteronemin in cancers
   Kuan Wang et al, 2022, Journal of Biomedical Science CrossRef
8. HER3 expression is correlated to distally located and low-grade colon cancer
   Frida Lédel et al, 2016, Acta Oncologica CrossRef
9. Dual targeting of HER3 and EGFR in colorectal tumors might overcome anti-EGFR resistance
   Sally Temraz et al, 2016, Critical Reviews in Oncology/Hematology CrossRef
10. MiR-323a regulates ErbB3/EGFR and blocks gefitinib resistance acquisition in colorectal cancer
    Yuanzhou Zhang et al, 2022, Cell Death & Disease CrossRef
11. Prediction model of poorly differentiated colorectal cancer (CRC) based on gut bacteria
    Zhang Qi et al, 2022, BMC Microbiology CrossRef